OverviewSuggest Edit

Oragenics is focused on becoming a leader in novel antibiotics against infectious disease and on developing effective treatments for oral mucositis. Oragenics, Inc. has established two exclusive worldwide channel collaborations with Intrexon Corporation Inc., a synthetic biology company. The collaborations allow Oragenics access to Intrexon's proprietary technologies toward the goal of accelerating the development of much needed new antibiotics that can work against resistant strains of bacteria and the development of biotherapeutics for oral mucositis and other diseases and conditions of the oral cavity, throat, and esophagus.

TypePublic
Founded1996
HQTampa, FL, US
Websiteoragenics.com

Latest Updates

Employees (est.) (Dec 2019)7(+17%)
Revenue (FY, 2017)$0
Share Price (Nov 2021)$0.6
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Oragenics

Charles L. Pope

Charles L. Pope

Director
Michael Sullivan

Michael Sullivan

Chief Financial Officer and Interim Principal Executive Officer
Alan Dunton

Alan Dunton

Director
Martin Handfield

Martin Handfield

Senior Vice President of Discovery Research
Robert Koski

Robert Koski

Director
Kim Murphy

Kim Murphy

Director
Show more

Oragenics Office Locations

Oragenics has an office in Tampa
Tampa, FL, US (HQ)
4902 Eisenhower Blvd N #125
Show all (1)

Oragenics Financials and Metrics

Oragenics Revenue

USD

Net income (Q1, 2021)

(5.2m)

EBIT (Q1, 2021)

(5.2m)

Market capitalization (12-Nov-2021)

71.8m

Closing stock price (12-Nov-2021)

0.6

Cash (31-Mar-2021)

36.5m

EV

36.0m
Oragenics's current market capitalization is $71.8 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

1.4m1.3m1.0m939.9k1.2m

Revenue growth, %

(9%)25%(100%)

Cost of goods sold

713.6k878.5k343.4k369.6k481.7k

Gross profit

730.8k453.3k688.9k570.3k694.1k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Revenue

347.6k350.4k380.5k256.4k176.4k167.7k253.4k214.7k303.8k201.0k363.8k242.0k329.8k262.3k

Cost of goods sold

328.8k134.4k198.2k112.3k63.9k86.7k113.4k79.8k125.6k73.7k168.0k86.8k134.6k90.0k

Gross profit

18.8k215.9k182.3k144.1k112.5k81.0k140.0k134.9k178.1k127.3k195.8k155.3k195.2k172.3k

Gross profit Margin, %

5%62%48%56%64%48%55%63%59%63%54%64%59%66%
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

171.7k9.9m16.3m10.4m5.1m4.1m6.2m20.2m18.3m17.6m

Accounts Receivable

92.6k69.8k64.4k15.6k21.1k24.1m

Prepaid Expenses

113.3k221.8k175.2k119.4k211.7k1.0m1.7m570.1k343.1k

Inventories

475.6k124.2k288.4k439.2k321.5k141.1k
USDQ2, 2011

Financial Leverage

-0.3 x
Show all financial metrics

Oragenics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

88/100

SecurityScorecard logo

Oragenics Online and Social Media Presence

Embed Graph

Oragenics News and Updates

Thinking about buying stock in Oragenics Inc, Fortress Biotech, Super League Gaming, CleanSpark Inc, or iBio Inc?

NEW YORK, Aug. 21, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OGEN, FBIO, SLGG, CLSK, and IBIO. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Thinking about buying stock in Oragenics Inc, Waitr Holdings, PDS Biotechnology, Novan Inc, or Ocugen Inc?

NEW YORK, July 22, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OGEN, WTRH, PDSB, NOVN, and OCGN. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Oragenics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

NEW YORK, Oct. 4, 2018 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Oragenics, Inc. (NYSE American: OGEN). If you...

Thinking about buying stock in DavidsTea, India Globalization Capital, Oragenics Inc, Stitch Fix or vTv Therapeutics?

NEW YORK, Oct. 3, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DTEA, IGC, OGEN, SFIX, and VTVT. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Oragenics Blogs

Oragenics Announces Positive COVID-19 Challenge Study Results Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate

Intranasal and Intramuscular Formulations were Assessed with Novel Adjuvants TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) today announced the results from its study to evaluate the immunogenicity and viral load reduction impact of its SARS…

Oragenics Awarded a $250,000 Grant from the National Institute of General Medical Sciences (NIGMS) for the Continued Research and Development of Lantibiotics.

TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) today announced that it was awarded a small business innovation research grant in the amount of $250,000 (“Computer-aided Design for Improved Lantibiotics” R41GM136034) for the Company’s continued…

Oragenics Initiates COVID-19 Challenge Study Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate

Intranasal and Intramuscular Formulations to be Assessed with Novel Adjuvants TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) today announced the initiation of a study to evaluate the immunogenicity and viral load reduction impact of its SARS…

Oragenics’ SARS-CoV-2 Spike Protein Produces Neutralizing Antibodies in Mice with Intramuscular and Intranasal Adjuvants

New data supports Company’s approach to COVID-19 vaccine development. TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN) (the Company) announces that the stabilized pre-fusion spike protein trimer produced by its Canadian collaborator and licensed by the Company from the Nati…

Oragenics Announces Postponement of Annual Meeting of Shareholders

TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN) Oragenics, Inc. (“Oragenics” or the “Company”) today announced the Company’s reconvened annual meeting of shareholders, on August 23, 2021 at 4:00 p.m. was adjourned due to a lack of quorum. The Company intends to seek approval…

Oragenics Enters into Licensing Agreement with the National Research Council of Canada, to Pursue the Rapid Development of Next-Generation SARS-CoV-2 Vaccines

Agreement provides Oragenics with antigen expression cell line technology capable of producing spike proteins within six to eight weeks of gene sequence definition Technology includes the ability to engineer vaccine antigens against SARS-CoV-2 including Wuhan, South African (beta) and other emer…
Show more

Oragenics Frequently Asked Questions

  • When was Oragenics founded?

    Oragenics was founded in 1996.

  • Who are Oragenics key executives?

    Oragenics's key executives are Charles L. Pope, Michael Sullivan and Alan Dunton.

  • How many employees does Oragenics have?

    Oragenics has 7 employees.

  • Who are Oragenics competitors?

    Competitors of Oragenics include Genprex, PreBiomics and Izun Pharmaceuticals.

  • Where is Oragenics headquarters?

    Oragenics headquarters is located at 4902 Eisenhower Blvd N #125, Tampa.

  • Where are Oragenics offices?

    Oragenics has an office in Tampa.

  • How many offices does Oragenics have?

    Oragenics has 1 office.